Regeneron Pharmaceuticals, Inc. (REGN) Operating Margin: 24.32%
Is Regeneron Pharmaceuticals, Inc.’s operating margin high or low?
Regeneron Pharmaceuticals, Inc.'s operating margin of 24.32% is 36% below its 5-year average of 38.03%, near the low end of its 5-year range (24.95%–55.67%).
The operating margin for Regeneron Pharmaceuticals, Inc. (REGN) is 24.32% as of Wednesday, June 10, 2026. It is below its 12-month average by 8.31% (26.52%).
REGN Operating Margin Chart
REGN Average Operating Margin Chart
REGN Current vs Average Operating Margin Chart
REGN Operating Margin Metrics
OPERATING MARGIN
24.32%
OPERATING MARGIN AVG TTM
26.52%
OPERATING MARGIN AVG 3Y
32.61%
OPERATING MARGIN AVG 5Y
38.03%
OPERATING MARGIN AVG 10Y
35.72%
OPERATING MARGIN AVG 15Y
26.48%
OPERATING MARGIN AVG 20Y
-3.91%
CURRENT VS TTM AVG
-8.31%
CURRENT VS 3Y AVG
-25.42%
CURRENT VS 5Y AVG
-36.06%
CURRENT VS 10Y AVG
-31.92%
CURRENT VS 15Y AVG
-8.15%
CURRENT VS 20Y AVG
+721.24%
REGN Competitors' Operating Margin
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. (REGN) | — | 24.32% | 26.52% | 32.61% | 38.03% |
| Cigna Corporation (CI) | $78.25B | 3.42% | 3.56% | 4.04% | 4.30% |
| IDEXX Laboratories, Inc. (IDXX) | $44.47B | 31.63% | 30.27% | 29.30% | 28.64% |
| Humana Inc. (HUM) | $43.78B | 1.01% | 1.25% | 2.37% | 3.27% |
| Elevance Health Inc. (ELV) | $87.43B | 3.81% | 4.55% | 4.90% | 5.40% |
| Agilent Technologies, Inc. (A) | $37.17B | 21.50% | 22.07% | 21.88% | 20.79% |
| Zoetis Inc. (ZTS) | $34.20B | 37.57% | 37.33% | 36.70% | 36.14% |
| Centene Corporation (CNC) | $31.94B | -3.68% | -0.98% | 0.21% | 0.84% |
| IQVIA Holdings Inc. (IQV) | $30.60B | 13.86% | 14.15% | 13.50% | 11.74% |
| DexCom, Inc. (DXCM) | $29.24B | 21.45% | 17.22% | 16.09% | 15.13% |
Operating Efficiency
Gross Margin
84.5%
Operating Margin
24.3%
Regeneron Pharmaceuticals, Inc. Operating Margin Formula & Definition
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Regeneron Pharmaceuticals, Inc. Operating Margin FAQ
- What is the operating margin for Regeneron Pharmaceuticals, Inc. (REGN)?
- The operating margin for REGN stock is 24.32%.
- Is Regeneron Pharmaceuticals, Inc.'s operating margin high or low?
- Regeneron Pharmaceuticals, Inc.'s operating margin of 24.32% is 36% below its 5-year average of 38.03%, near the low end of its 5-year range (24.95%–55.67%).
- What is the TTM average operating margin for Regeneron Pharmaceuticals, Inc. (REGN)?
- The TTM average operating margin for REGN stock is 26.52%.
- What is the 3Y average operating margin for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 3Y average operating margin for REGN stock is 32.61%.
- What is the 5Y average operating margin for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 5Y average operating margin for REGN stock is 38.03%.
- What is the 10Y average operating margin for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 10Y average operating margin for REGN stock is 35.72%.
- What is the 15Y average operating margin for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 15Y average operating margin for REGN stock is 26.48%.
- What is the 20Y average operating margin for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 20Y average operating margin for REGN stock is -3.91%.
Regeneron Pharmaceuticals, Inc. Operating Margin History
| DATE | OPERATING MARGIN |
|---|---|
| 2025-12-31 | 24.95% |
| 2024-12-31 | 28.10% |
| 2023-12-31 | 33.15% |
| 2022-12-31 | 44.24% |
| 2021-12-31 | 55.67% |
| 2020-12-31 | 42.09% |
| 2019-12-31 | 33.70% |
| 2018-12-31 | 37.77% |
| 2017-12-31 | 35.41% |
| 2016-12-31 | 27.38% |
| 2015-12-31 | 30.51% |
| 2014-12-31 | 29.22% |
| 2013-12-31 | 35.30% |
| 2012-12-31 | 33.41% |
| 2011-12-31 | -46.02% |
| 2010-12-31 | -21.23% |
| 2009-12-31 | -19.54% |
| 2008-12-31 | -37.67% |
| 2007-12-31 | -91.55% |
| 2006-12-31 | -169.13% |
| 2005-12-31 | -187.97% |
| 2004-12-31 | 3.24% |
| 2003-12-31 | -173.90% |
| 2002-12-31 | -554.63% |
| 2001-12-31 | -389.95% |
| 2000-12-31 | -42.64% |
| 1999-12-31 | -68.99% |
| 1998-12-31 | -32.72% |
| 1997-12-31 | -22.66% |
| 1996-12-31 | -71.78% |
Related Metrics
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Leonard S. Schleifer